NCT05445076View on ClinicalTrials.gov

Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

250

Participants

Timeline

Start Date

April 19, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2027

Conditions
Axial Spondyloarthritis
Interventions
BIOLOGICAL

anti-TRBV9 monoclonal antibody, low dose

infusion

BIOLOGICAL

anti-TRBV9 monoclonal antibody, high dose

infusion

OTHER

placebo

infusion

Trial Locations (2)

Unknown

Clinical Rheumatology Hospital №25, Saint Petersburg

North-Western state Medical University named after I.I. Mechnikov, Saint Petersburg

Sponsors

Lead Sponsor

Biocad
All Listed Sponsors
lead

Biocad

INDUSTRY

NCT05445076 - Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis | Biotech Hunter | Biotech Hunter